V-ATPase α1 Activators, comprising a variety of compounds, indirectly modulate the activity of V-ATPase α1, a crucial subunit of the vacuolar-type H+-ATPase involved in intracellular acidification processes. Key activators such as Bafilomycin A1, Concanamycin A, and Folimycin are known inhibitors of V-ATPase α1. However, their inhibitory action triggers compensatory cellular responses, leading to an upregulation of V-ATPase α1. This upregulation is essential to maintain intracellular pH homeostasis and lysosomal acidification, critical for cellular functions like protein degradation, endocytosis, and autophagy. Other compounds such as Escin and Saliphenylhalamide, by affecting membrane permeability or directly inhibiting V-ATPase α1, respectively, also induce a compensatory increase in V-ATPase α1 activity. This enhancement is vital for sustaining organelle acidification under varying cellular conditions. Trace elements like Zinc and Copper can bind to V-ATPase α1, altering its activity, which may lead to adaptive cellular responses that increase its function, crucial for regulating intracellular acidification. Nitric Oxide Donors represent another category of indirect activators, modulating cellular signaling pathways that affect V-ATPase expression and activity.
Additionally, compounds such as Glucosamine, Chloroquine, Amiloride, and Monensin indirectly influence V-ATPase α1 activity through various mechanisms. Glucosamine impacts glycosylation processes, potentially affecting V-ATPase localization and stability, leading to enhanced activity in organelle acidification. Chloroquine, by inhibiting lysosomal function, necessitates a compensatory increase in V-ATPase α1 activity to maintain lysosomal pH and function. Amiloride and Monensin, affecting ion transport and cellular pH, indirectly enhance V-ATPase α1 activity as a response to disrupted acidification in cellular organelles. Collectively, these V-ATPase α1 Activators, through their indirect actions, play a significant role in regulating the functionality of V-ATPase α1, ensuring its critical role in maintaining cellular pH balance and organelle function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A, similar to Bafilomycin A1, inhibits V-ATPase α1, resulting in a compensatory increase in V-ATPase α1 expression and activity to sustain intracellular pH homeostasis and lysosomal acidification. | ||||||
Escin | 6805-41-0 | sc-221596 sc-221596A sc-221596B | 1 g 5 g 10 g | $68.00 $238.00 $286.00 | 5 | |
Escin indirectly enhances V-ATPase α1 activity by affecting membrane permeability and potentially increasing the cellular demand for V-ATPase α1 in maintaining ion homeostasis and organelle acidification. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc can indirectly enhance V-ATPase α1 activity by binding to V-ATPase and affecting its conformation, which might lead to a compensatory increase in the enzyme's activity to maintain cellular pH balance. | ||||||
Copper | 7440-50-8 | sc-211129 | 100 g | $51.00 | ||
Copper, similar to Zinc, may bind to V-ATPase α1 and alter its activity, potentially leading to adaptive cellular responses that increase V-ATPase α1 activity to regulate intracellular acidification. | ||||||
D-Glucosamine | 3416-24-8 | sc-278917A sc-278917 | 1 g 10 g | $201.00 $779.00 | ||
Glucosamine indirectly enhances V-ATPase α1 activity by influencing glycosylation processes, which may affect V-ATPase localization and stability, leading to increased activity in organelle acidification. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, by inhibiting lysosomal function, indirectly enhances V-ATPase α1 activity through compensatory mechanisms to maintain lysosomal pH and function, essential for protein degradation and autophagy. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride, primarily a diuretic, can indirectly enhance V-ATPase α1 activity by affecting ion transport and pH regulation, potentially leading to increased demand for V-ATPase α1 in organelles like lysosomes. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin, by disrupting ion transport and cellular pH, indirectly enhances V-ATPase α1 activity as a compensatory mechanism to maintain acidification in organelles such as lysosomes and endosomes. | ||||||